Aclaris Therapeutics Inc. (ACRS)
NASDAQ: ACRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACRS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $545.63M
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 2.46 – 6.60
- Day range
- 3.40 – 3.54
- Volume / Avg
- 2.19M / 3.07M
- Beta
- —
- Shares outstanding
- 158.61M
52-week range
ACRS stock today
Shares of Aclaris Therapeutics (ACRS) finished lower on Nov 20 at $3.44, a drop of 1.71% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 47.9% below their 52-week high of $6.60, set on Aug 25, 2026 and 39.8% above the 52-week low of $2.46, in the middle of the past year's range. ACRS is up 14.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 37.1%.
Aclaris Therapeutics has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aclaris Therapeutics
Company profileAclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Neal S. Walker D.O., M.D.
- Headquarters
- Wayne, PA
- Employees
- 69
- IPO year
- 2015
- Website
- aclaristx.com
Financial highlights
Full financialsIn fiscal 2025, Aclaris Therapeutics generated $7.8 million in revenue, down 58.2% from fiscal 2024, its first annual decline since 2024. Aclaris Therapeutics reported a net loss of $64.9 million, compared with a loss of $132.1 million a year earlier. Gross margin was 73.3% (down from 85.1%) and operating margin -975.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M |
| Growth | -58.19% | -40.09% | +5.03% | +340.05% | +4.30% |
| Net income | $-64.92M | $-132.06M | $-88.48M | $-86.91M | $-90.86M |
| EPS (diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$10.50+205.23%
- Strong buy 1
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.12 vs $-0.16
- Surprise
- +25.00%
ACRS news
All ACRS news- Why is Aclaris Therapeutics stock sliding today?Investing.com
- Aclaris Launched Phase 2b Trial Of Modzatinib For Lichen Planus; Stock DownNasdaqACRS, ET
- Aclaris Therapeutics, Inc. Announces Phase 2 Trial Results for Bosakitug and Initiates Phase 2b ALPHA Trial of ModzatinibNasdaq
- Aclaris Reports Bosakitug Phase 2 Setback, Focuses To Other Pipeline ProgramsNasdaqACRS, MKC.V
- Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)GlobeNewswire
- Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)GlobeNewswire
- Aclaris Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Aclaris Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
Aclaris Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs ACRS |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs ACRS |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs ACRS |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs ACRS |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs ACRS |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs ACRS |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs ACRS |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs ACRS |
Indexes, lists and sector
Aclaris Therapeutics stock FAQ
What is Aclaris Therapeutics's stock price today?
ACRS last traded at $3.44 as of Nov 20, 4:00 PM EST, down 1.71% on the day. Prices are delayed at least 15 minutes.
Who is Aclaris Therapeutics's CEO?
Dr. Neal S. Walker D.O., M.D. is the chief executive officer of Aclaris Therapeutics Inc., which has about 69 employees.
What is the ACRS 52-week high?
The 52-week high for ACRS is $6.60 and the 52-week low is $2.46. The stock is currently 47.9% below its high.